About: Immunocapture-based ELISA to characterize and quantify exosomes in both cell culture supernatants and body fluids

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunocapture-based ELISA to characterize and quantify exosomes in both cell culture supernatants and body fluids Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Immunocapture-based ELISA to characterize and quantify exosomes in both cell culture supernatants and body fluids
Creator	Fais, Stefano Logozzi, Mariantonia Mizzoni, Davide Raimo, Rossella
source	Elsevier; PMC
abstract	The immunocapture-based ELISA for extracellular vesicles (EVs)/exosomes, originally described in 2009 by Logozzi and colleagues, allows to capture, detect, characterize and quantify extracellular vesicles in both human body fluids and cell culture supernatants. It is based on the use of two antibodies directed one against a typical exosomal housekeeping protein and the second against either another exosomal housekeeping protein or a potential disease marker: the first antibody is used for the capture of exosomes, the second for the quantification and characterization of the captured vesicles. In fact, with this method it is possible both to characterize and count exosomes and to detect the presence of disease, including tumor, biomarkers. This needs of course to preliminary obtain an EVs purification from the clinical sample; the most agreed method to get to an EVs purification is the repeated rounds of ultracentrifugation, that, while far to be perfect, is the methodological approach allowing to not exclude EVs subpopulation from the separation procedure and to analyze a full range of EVs from both qualitative and quantitative point of view. The immunocapture-based approach has proven to be highly useful in screening, diagnosis and prognosis of tumors, in plasma samples. One amazing information provided by this method is that cancer patients have always significantly higher levels of EVs, in particular of exosomes, independently from the histological nature of the tumor. One microenvironmental factor that is fully involved in the increased exosome release by tumors is the extracellular acidity. However, few pre-clinical data suggest that plasmatic levels of exosomes may correlate with the tumor mass. Some recent clinical reports suggest also that circulating exosomes represent the real delivery system for some known tumor markers that are presently on trial (e.g., PSA). Here we review the pros and cons of the immunocapture-based technique in quantitative and qualitative evaluation of EVs in both health and disease.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1016/bs.mie.2020.06.011
has license	no-cc
sha1sum (hex)	b32bd9625b1991537c0ae95475551afd27c54d64
schema:url	https://doi.org/10.1016/bs.mie.2020.06.011
resource representing a document's title	Immunocapture-based ELISA to characterize and quantify exosomes in both cell culture supernatants and body fluids
has PubMed Central identifier	PMC7346819
schema:publication	Methods Enzymol
resource representing a document's body	covid:b32bd9625b1991537c0ae95475551afd27c54d64#body_text
is schema:about of	named entity '2009' named entity 'cell culture' named entity 'HUMAN BODY' named entity 'Enzymology' named entity 'housekeeping' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software